11 (Bloomberg) -- Shire Plc agreed to buy ViroPharma Inc. for about $4.2 billion to gain treatments for rare diseases and ease dependence on its best-selling Vyvanse pill for attention deficit hyperactivity disorder.
ViroPharma Inc VPHM.O, a drug maker that specializes in rare diseases, has attracted interest from Sanofi SA (SASY.PA) and Shire PLC (SHP.L), Bloomberg reported on Friday, pushing shares of the company up 24 percent. Reuters reported in June that the ...
The 25% boost in ViroPharma Inc.'s share price stayed steady but support for Shire plc started to slide toward the breakeven point in Monday morning trades as investors digested the prospects of a merger between the two biotechnology companies.
Philadelphia Business Journal (blog) - Jan 15, 2014
Shire said Wednesday it has waived the Office of Fair Trading approval condition that was part of its previously announced $50 per share tender offer for all of the outstanding shares of ViroPharma Inc. The London-based Office of Fair Trading [OFT] is ...
Philadelphia Business Journal (blog) - Dec 31, 2013
Shire has extended its previously announced tender offer for all of the outstanding common shares of ViroPharma until midnight on Jan. 9. All of the other terms and conditions of the $50 per share tender offer remain unchanged.